Literature DB >> 2921982

Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors.

R W Howell1, D V Rao, K S Sastry.   

Abstract

In the context of radioimmunotherapy of cancer, there is a need for continued improvement of dosimetry of radionuclides localized in tumors. Current methods assume uniform distribution of radionuclides in the tumor despite experimental evidence indicating nonuniormity. We have developed a model in which nonuniform distribution of radioactivity in the tumor is taken into account. Spherically symmetric radionuclide distributions, depending linearly and exponentially on the radial position, are considered. Dose rate profiles in the tumor are calculated for potentially useful beta-emitting radionuclides, including 32P, 67Cu, 90Y, 111Ag, 131I, and 188Re, and for 193mPt, an emitter of conversion electrons and low-energy Auger electrons. For the radionuclide distributions investigated, high-energy beta emitters, such as 90Y, are most effective in treating large tumors (diameter, d greater than approximately 1 cm), whereas for small tumors (d approximately 1 mm), medium energy beta emitters such as 67Cu are better suited. Very small tumors (d less than 1 mm), and micrometastases are best handled with low-energy electron emitters such as 193mPt.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2921982     DOI: 10.1118/1.596404

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  22 in total

1.  When may a nonuniform distribution of 131I be considered uniform? An experimental basis for multicellular dosimetry.

Authors:  Prasad V S V Neti; Roger W Howell
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

2.  A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.

Authors:  John M Akudugu; Roger W Howell
Journal:  Nucl Med Biol       Date:  2012-04-14       Impact factor: 2.408

Review 3.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.

Authors:  Raghu Raghavan; Roger W Howell; Michael R Zalutsky
Journal:  Biomed Phys Eng Express       Date:  2017-05-05

5.  A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.

Authors:  Robert F Hobbs; Sébastien Baechler; De-Xue Fu; Caroline Esaias; Martin G Pomper; Richard F Ambinder; George Sgouros
Journal:  Med Phys       Date:  2011-06       Impact factor: 4.071

6.  Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.

Authors:  R W Howell; S M Goddu; D V Rao
Journal:  Med Phys       Date:  1998-01       Impact factor: 4.071

7.  Survival of tumor and normal cells upon targeting with electron-emitting radionuclides.

Authors:  Didier Rajon; Wesley E Bolch; Roger W Howell
Journal:  Med Phys       Date:  2013-01       Impact factor: 4.071

8.  Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs.

Authors:  John M Akudugu; Roger W Howell
Journal:  Int J Radiat Biol       Date:  2011-12-09       Impact factor: 2.694

9.  Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.

Authors:  Pilar de la Puente; Nicole Fettig; Micah J Luderer; Abbey Jin; Shruti Shah; Barbara Muz; Vaishali Kapoor; Sreekrishna M Goddu; Noha Nabil Salama; Christina Tsien; Dinesh Thotala; Kooresh Shoghi; Buck Rogers; Abdel Kareem Azab
Journal:  J Pharm Sci       Date:  2017-11-21       Impact factor: 3.534

Review 10.  Three-dimensional imaging-based radiobiological dosimetry.

Authors:  George Sgouros; Eric Frey; Richard Wahl; Bin He; Andrew Prideaux; Robert Hobbs
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.